CTA

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
Giovedì, Maggio 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on: 
Mercoledì, Maggio 8, 2024
CTA, CD22, HIP, Contingency, Cell Stem Cell, CD47, Lupus nephritis, Cell, Insulin, Safety, ANCA, Organoid, Research, Survival, Immunosuppression, Research and development, B cell, Development, VIVID, GLEAM, Administration, Autoimmunity, Exercise, Biotechnology, CD19, Patent, Sana, Patient, Regeneration, NHP, Diabetes, Cancer, Lymphoid leukemia, GAAP, Organization, Escape Room, Vaccine

Enrollment in this study continues, and Sana expects to share more data in 2024.

Key Points: 
  • Enrollment in this study continues, and Sana expects to share more data in 2024.
  • The trial has begun enrollment, and Sana expects to share initial data in 2024.
  • The trial has begun enrollment, and Sana expects to share initial data in 2024.
  • The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects to share initial data in the first half of 2024.

HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients

Retrieved on: 
Mercoledì, Maggio 8, 2024
Mortality, CTA, Coronary artery disease, Risk, PAD, Heart, Atherosclerosis, Moyamoya disease, Senior, Patient, CAD, Physician, Myocardial infarction, Diagnosis, Health, CCTA, Journal, Pharmaceutical industry

“PAD affects over 230 million people globally, presenting a significantly underrecognized risk of CAD,” said Dr. Frank Arko, Chief of Vascular and Endovascular Surgery at Atrium Health Sanger Heart & Vascular Institute.

Key Points: 
  • “PAD affects over 230 million people globally, presenting a significantly underrecognized risk of CAD,” said Dr. Frank Arko, Chief of Vascular and Endovascular Surgery at Atrium Health Sanger Heart & Vascular Institute.
  • “In an additional study looking at a similar patient population, we studied 170 high-risk PAD patients, where we utilized systematic FFRCT testing.
  • Remarkably, 70 percent of these patients had hemodynamically significant CAD, which is a major risk factor for cardiac complications.
  • This publication showcases the company’s continued commitment to revolutionizing patient care with innovative and scientifically validated technologies.

Immunocore reports first quarter financial results and provides a business update

Retrieved on: 
Mercoledì, Maggio 8, 2024
CTA, Total, Research, HLA, IND, ASCO, Research and development, BMY, Annual report, Drug, Autoimmune disease, APC, HIV, Bristol Myers Squibb, TCR, Autoimmunity, Infection, PRAME, Treatment, EMA, GMP, Clinical trial, Investigational New Drug, Platinum, ImmTAC, Nivolumab, Security (finance), Form 10-Q, Half-life, Patient, Immune system, Pharmaceutical industry

& ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided a business update.
  • Net loss for the first quarter of 2024 was $24.4 million compared to a net loss of $19.4 million in the same period in 2023.
  • The first quarter basic and diluted loss per share was $0.49, compared to $0.40 for the first quarter of 2023.
  • This includes net cash proceeds of $390.2 million from the Company’s offering of convertible notes in February 2024.

Fortinet Reaffirms Its Commitment to Secure Product Development Processes and Responsible Vulnerability Disclosure Policies

Retrieved on: 
Martedì, Maggio 7, 2024
CTA, Fortinet, Design, Intelligence, Risk management, Culture, Organization, Privacy, Private sector, RSA, Disclosure, GDPR, Software, Communication, Conference, ISO, System, NIST, Network, Joint, Certification, Consultant, SAST, Default, CCPA, Political lists, DAST, Undersecretary, TAA, Environment, Senior, C4C, Education outreach, CISA, Medical device

“At Fortinet, we have a long-standing commitment to being a role model in ethical and responsible product development and vulnerability disclosure.

Key Points: 
  • “At Fortinet, we have a long-standing commitment to being a role model in ethical and responsible product development and vulnerability disclosure.
  • The pledge outlines seven goals, including responsible vulnerability disclosure policies, which are already an integral part of Fortinet’s product security development .
  • CISA’s latest initiative strongly aligns to Fortinet’s existing product development processes already based on Secure by Design and Secure by Default principles.
  • Fortinet’s commitment to data privacy and security is embedded in every part of the company’s business and in every phase of the product development, manufacturing, and delivery processes.

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Retrieved on: 
Martedì, Maggio 7, 2024
Sentinel, Sickle cell disease, CTA, Medication, Investment, Security, Hematology, Deference, IND, Administration, Research and development, Patient, Lung, ESCAPE, Clinical trial, Biotechnology, G&A, AATD, Pharmaceutical industry

CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2024 financial results and provided updates across the company’s hematology and genetic disease franchises.

Key Points: 
  • The company expects to report data from multiple patients in the BEACON trial in the second half of 2024.
  • Beam expects to initiate the Phase 1/2 clinical trial for BEAM-302 in AATD in the first half of 2024.
  • Research & Development (R&D) Expenses: R&D expenses were $84.8 million for the first quarter of 2024, compared to $99.6 million for the first quarter of 2023.
  • General & Administrative (G&A) Expenses: G&A expenses were $26.7 million for the first quarter of 2024, compared to $23.5 million for the first quarter of 2023.

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Martedì, Maggio 7, 2024
Research, Medical Devices, FDA, Genetics, Health Technology, Biotechnology, Health, Other Science, Science, CTA, Fast Track, Safety, Pharmacokinetics, Food, European Commission, OTC, Gene editing, Communication, Collection, IND, Therapy, Precision BioSciences, Patient, Civil service commission, Standard of care, Precision, Vaccine

ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.

Key Points: 
  • ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.
  • The Fast Track designation is designed to facilitate the development and expedite the review of therapeutics to treat serious conditions that fill an unmet medical need.
  • Provided relevant criteria are met, programs with Fast Track designation are eligible for accelerated approval and priority review as well.
  • “Congratulations to iECURE for this significant regulatory designation and for what it can potentially mean to patients with neonatal onset OTC deficiency.

Mixmax Launches New Integration With HubSpot, Empowering Revenue Teams to Reach More Buyers

Retrieved on: 
Martedì, Maggio 7, 2024
SMS, CTA, CRM, HubSpot, Account executive, SAN, Sales

SAN FRANCISCO, May 7, 2024 /PRNewswire-PRWeb/ -- Mixmax, the easiest-to-use sales engagement platform, today announced the launch of its new HubSpot integration. This will enable HubSpot CRM users to reach more buyers using Mixmax's AI-powered sales engagement solution.

Key Points: 
  • SAN FRANCISCO, May 7, 2024 /PRNewswire-PRWeb/ -- Mixmax, the easiest-to-use sales engagement platform , today announced the launch of its new HubSpot integration.
  • This will enable HubSpot CRM users to reach more buyers using Mixmax's AI-powered sales engagement solution.
  • Mixmax offers guidance on who to reach out to, the best time and channels to maximize engagement, and what messages resonate most with buyers.
  • "Mixmax is a great fit for HubSpot CRM users who want to reach more buyers with a more advanced suite of sales engagement features.

FincenFetch, Pearce Law Group Join Forces to Get Businesses Compliant Under the New Corporate Transparency Act Guidelines

Retrieved on: 
Lunedì, Maggio 6, 2024
CTA, Financial Crimes Enforcement Network, AI, Treasury, Partnership, Automation, BOI, Beneficial ownership, File, Financial adviser

FT. LAUDERDALE, Fla., May 6, 2024 /PRNewswire-PRWeb/ -- FincenFetch, an industry-leading Beneficial Ownership Information Report (BOI) filing software solution, recently joined forces with Pearce Law Group LLC to provide an AI-powered platform to keep clients compliant under the new Corporate Transparency Act (CTA) guidelines.

Key Points: 
  • FincenFetch, an industry-leading Beneficial Ownership Information Report (BOI) filing software solution, recently joined forces with Pearce Law Group LLC to provide an AI-powered platform to keep clients compliant under the new Corporate Transparency Act (CTA) guidelines.
  • FT. LAUDERDALE, Fla., May 6, 2024 /PRNewswire-PRWeb/ -- FincenFetch, an industry-leading Beneficial Ownership Information Report (BOI) filing software solution, recently joined forces with Pearce Law Group LLC to provide an AI-powered platform to keep clients compliant under the new Corporate Transparency Act (CTA) guidelines.
  • "With the adoption of FincenFetch's automated BOR filing, we've been able to enrich our client services with ease," said Pearce Law Group Attorney L. Raymond Wells.
  • "Our partnership with Pearce Law Group and other high-profile firms is proof positive that our technical and innovative capabilities make compliance easier.

Medigene presents streamlined 6-day, high stemness TCR-T therapy production process

Retrieved on: 
Giovedì, Aprile 25, 2024
CTA, Synovial sarcoma, Safety, Cytokine, MD, Stomach, DP, Interferon, PD-L1, CHI, Patient, Neoplasm, CSP, DPS, CTAS, TCR, Ovarian cancer, Vaccine

Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.

Key Points: 
  • Medigene tackles these challenges with a comprehensive approach, which starts with the development of a potential best-in-class, 3S (sensitive, specific, and safe) TCR.
  • This process is vital for producing effective, safe, and durable TCR-T therapies," stated Kirsty Crame, MD, VP Clinical Strategy & Development.
  • Medigene has developed a streamlined 6-day manufacturing process that focuses on the enrichment of CD8+ T cells whilst simultaneously maintaining a high degree of stemness.
  • Clinical indications for MDG1015 were primarily chosen based on the high unmet medical need, expression of the target antigen and/or PD-L1.